Doctor discusses Ivermectin success in India, questions Canada’s COVID approach
03/12/2021 No Comments
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
An American football quarterback for the Green Bay Packers declared yesterday he was recovering from COVID-19 and had taken a set of medications early
Dr. Pierre Kory gives a clinic on big pharma’s capture of mainstream media, big tech, medical journals, and governments. “They don’t care if people die.”
Researchers at the MUSC are now conducting clinical trials to help fight against COVID-19, but to settle questions surrounding the drug Ivermectin.
In El Salvador, the Ministry of Public Health has embraced Ivermectin as part of a combination of recommendations for early treatment of COVID-19
Risk and benefit analysis suggests if a drug with a well-established, safe profile can help then why wouldn’t such a drug be used?
Dr Stramezzi talks about his experience, his perspectives on treatment of Covid-19, his telemedicine service & the upcoming International Covid Summit in Rome in September.
This is a far reaching interview with Nick Hudson, who is the leader of PANDA, which stands for Pandemics Data & Analytics
This interview with Steve Kirsch features early treatment, vaccination, government responses to pandemics, tech companies & freedom of expression.
Dr George Fareed provides an update about the outpatient treatment of COVID-19, for newly infected and for long covid patients.
This interview features Dr Caxton Opere, who has not only treated C19 patients but also written 3 books about it, the first one in early April 2020.
Those who design the trials and control the data also control the outcome. So this system of industry-led trials needs to be put to an end.
The results not only provide a structural basis for the anti-SARS-CoV-2 activity of HCQ, but also renders HCQ to be the first known drug capable of targeting LLPS.
Just as fast as new cases materialized so has the decline thanks in part to a coordinated public health strategy that includes proactive testing, home visits, and medication kits that include ivermectin.
“The significant decline is a tremendous achievement in the fight against COVID-19 and further bolsters our appeal to undertake mass distribution of ivermectin to our people.”
With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19.
The kits distributed included ivermectin, aspirin and paracetamol. Between the end of November 2020 and the end of January 2021, more than 200,000 people tested positive for COVID, and of these, nearly 80,000 used the ivermectin kits. Results showed up to 76% reduction in hospitalization in the group that was taking ivermectin.
Zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group), the results were overall impressive.
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported
To say that hydroxychloroquine and ivermectin kill is a fallacy. Who wants to do the early treatment, do it. Whoever doesn’t want it, don’t do it
None of the 788 who took 12mg of ivermectin weekly became ill with Covid vs 58% out of 407 control subjects
A Utah pharmacist accused of illegally receiving a controversial coronavirus drug “had a green light from a lot of very prominent Utah authorities to do exactly what he did,” his defense attorney asserts.
In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
From my patients who are treated by me from the beginning, I have had no deaths.
A doctor and outspoken critic of the coronavirus vaccine was among those who entered the Capitol building last week during the siege that disrupted the certification of the 2020 presidential election.
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
Hydroxychloroquine is an effective molecule against COVID-19 infection, many RCTs and observational studies, affirmed the benefits on virological clearance.
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
From there, we had an abrupt drop in our curve… we did more than 50,000 treatments… after we started the treatment early, we had no more than 5% hospitalization
It is impossible to say that a drug with an extensively documented and strong safety record for 65 years is dangerous but a brand new medication is safe.
Bengal has released this document to state their COVID-19 policies, which include the use of HCQ. Well done Bengal.
While Professor Raoult was testing, isolating and treating his patients, the government decided to send the patients home, without care and with Doliprane for only treatment!
The early use of
hydroxychloroquine decreased the improvement time
and the duration of COVID-19 detection in throat and
stool swabs.
Ivermectin. It basically obliterates transmission of this virus. Early treatment is key. That is a scientific recommendation based on mountains of data
I want some doctor somewhere to explain to me, and if they can explain to me why we’re not treating early I would gladly offer them a million dollars.
Figure 3 reported random forest for 10 studies comparing HCQ+AZM. Use of the combination HCQ+AZM was associated with 25% lower mortality risk
The TMB stated that there was insufficient evidence to prove that a violation of the Medical Practice Act [had] occurred when reviewing Dr Urso
While numerous studies have now proven this to be so, and the practical experiences of several doctors with numerous patients have shown that, as part of a package of quality outpatient care, the drug can play an important role in reducing the need for hospitalization and the mortality risk.
Professor Raoult had very quickly sent a “warning letter” to the newspaper about this study which seemed to him incomplete and including too much bias.
This unprecedented violation of the sanctity of the doctor-patient relationship, denying Australians access to this drug, must end.